comparative study of htlv i/ii seroprevalence between two periods of time in buenos aires, argentina.

NLM AIDSLINE Comparative study of HTLV I/II seroprevalence between two periods of time in Buenos Aires, Argentina. Vazquez AO; Deluchi J; Canizal A; Castro R; Benetucci J; Laboratorio de
January 30, 1997

Int Conf AIDS. 1996 Jul 7-12;11(1):169 (abstract no. Mo.C.1670). Unique Objective: Comparison of HTLV I/II seroprevalence between two groups. Methods: 2815 serum samples obtained from two groups of free testing patients seeking for HIV, (A) since june to september 1994 and (B) in the same period of 1995, were tested for HTLV I/II antibodies by PA (Serodia, Fujirebio) and ELISA HTLV Organon Teknika) as screening. Reactives samples were confirmed by IFA (in house). IFA reactives were tested by a modified Western Blot (HTLV 2. 3Blot D.B) in order to distinguish between both HTLV types. Heterosexuals= HET, men who have sex with men= MSM, injecting drug users= IDUS.(table: see text) Conclusions: The results confirm that idu's were the most exposed to the transmission. Although the rate between heterosexual and MEM is remarkable. If we compare the two groups we obtained no significative difference between both periods of time. HTLV-I Infections/EPIDEMIOLOGY HTLV-II Infections/EPIDEMIOLOGY

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV No time to lose in the search for an HIV vaccine India Widens Price Control Over Medicines Health group didn't disclose HIV tests, apologizes As Hepatitis C Spreads, Scotland Steps In Russia has 'no anti-AIDS strategy': official Uganda: Over 600 Circumcised in Masaka 1 new hepatitis case in Okla. public health scare NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs No time to lose in the search for an HIV vaccine Researchers from Albert Einstein College of Medicine Report Details of New Studies and Findings in the Area of HIV/AIDS NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative Uganda: Breastfeeding Lowers HIV Transmission - Study Study Results from Eunice Kennedy Shriver National Institute of Child Health and Human Development Provide New Insights into HIV/AIDS HIV Vaccine Study Cancelled Less-used drug better treats HIV in kids: study UNITED STATES: Study Suggests PrEP May Not Increase Sexual Risk-Taking in Gay Men UNITED STATES: Study Suggests PrEP May Not Increase Sexual Risk-Taking in Gay Men UNITED STATES: Study Suggests PrEP May Not Increase Sexual Risk-Taking in Gay Men
Information in this article was accurate in January 30, 1997. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.